News
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.
InvestorsHub on MSN2d
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTIEvoke Pharma Inc (NASDAQ:EVOK) saw its stock soar 50% after the specialty pharma company received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering ...
Opinion: Retired federal appeals court judges Paul Michel and Kathleen O'Malley say Congress should pass legislation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback